LANGFANG, China, Nov. 25, 2025 /PRNewswire/ — TÜV Rheinland, an independent global provider of testing, inspection, and certification services, has signed a cooperation agreement with the National Elevator Inspection and Testing Centre (NETEC). The agreement focuses on coordinated fire door testing for the Singapore market and was formalized at a ceremony in Langfang, Hebei Province.

Under the agreement, TÜV Rheinland recognizes NETEC’s fire prevention laboratory to conduct testing activities that support TÜV Rheinland’s independent certification work. The collaboration applies to fire-rated lift landing doors tested in accordance with BS 476-22 and EN 81-58. TÜV Rheinland remains responsible for issuing Certificates of Compliance (CoC) under its accredited scope.

Since April 2025, TÜV Rheinland has been an approved certification body under the Singapore Civil Defence Force (SCDF) Product Listing Scheme (PLS). This accreditation covers fire safety products listed under SCDF Table 11A, including lift landing doors.

The cooperation acknowledges NETEC’s testing capabilities and establishes a coordinated approach that supports manufacturers seeking access to Singapore’s fire safety requirements. Both organizations will focus on clear processes from testing to certification while maintaining strict separation of roles to uphold independence and impartiality.

“This cooperation with TÜV Rheinland is an important step in NETEC’s international development,” said Mr. Zhou Chunming of NETEC. “We look forward to contributing our technical expertise in elevators, construction machinery, and fire prevention to support this work. Together, we aim to provide reliable technical services that help customers understand and meet relevant regulatory requirements in domestic and international markets.”

“This collaboration reflects our commitment to supporting safe and compliant access to global markets,” said Mr. Sun Guorong of TÜV Rheinland. “Working with NETEC’s fire safety laboratory allows us to align testing workflows while maintaining independent certification according to our accredited scope. Our shared focus is to support manufacturers with clear, consistent, and technically robust certification processes.”

TÜV Rheinland and NETEC also expressed interest in exploring additional areas of technical cooperation in line with regulatory frameworks and accreditation requirements. Future discussions may cover elevators, machinery components, building construction, and aerial work equipment.

TÜV Rheinland Singapore continues to provide product certification services within its accredited scope and supports manufacturers seeking access to regulated markets, including Singapore under SCDF requirements and the EU for CE marking of lift landing doors, building materials, and fire safety products. The focus remains on clear processes, regulatory compliance, and consistent technical assessment across markets.

About TÜV Rheinland:

150 years of making the world a safer place: TÜV Rheinland is one of the world’s leading providers of testing and inspection services, with annual revenues of over 2.7 billion euros and approximately 27,000 employees in more than 50 countries. Its highly qualified experts test technical systems and products, enable innovation, and assist companies in their transition toward greater sustainability. They train professionals across numerous fields and certify management systems to international standards. With exceptional expertise in areas such as mobility, energy supply, infrastructure, and beyond, TÜV Rheinland provides independent quality assurance—not least for emergent technologies such as green hydrogen, artificial intelligence and autonomous driving. In doing so, TÜV Rheinland contributes to a safer and better future for everyone. Since 2006, TÜV Rheinland has been a signatory to the UN Global Compact, which promotes sustainability and combats corruption. The company’s headquarter is in Cologne, Germany. Website: www.tuv.com

About TÜV Rheinland Singapore:

TÜV Rheinland Singapore, established in 1989, has been a trusted partner in testing, inspection, and certification for more than three decades. Over the years, we expanded our services to strengthen our position in the TIC (Testing, Inspection and Certification) industry. Since February 2025, TÜV Rheinland Singapore is accredited to ISO 17065 by Singapore Accreditation Council (SAC), for Product Listing Scheme (PLS) and BC1.

For media inquiries, please contact:
Email: info@sin.tuv.com
Phone: +65 6799 0300

SHANGHAI, Nov. 25, 2025 /PRNewswire/ — The Shanghai World of Packaging (swop), co-organized by Messe Düsseldorf (Shanghai) Co., Ltd. and Adsale Exhibition Services Ltd., took place from November 25–27, 2025, at SNIEC (Shanghai New International Expo Centre).

This year, swop reaches the significant milestone of its 10th anniversary. Since its debut in 2015, swop has evolved into a major annual international exhibition for the global packaging industry. The show has always maintained its long-standing commitment to staying current with industry developments and remaining closely aligned with the sector. swop 2025 showcased numerous innovative packaging products and technologies. It focused on eight end-use sectors—food, beverages, confectionery, bakery, pharmaceuticals, cosmetics, non-food consumer goods, and industrial products—and kept pace with developments at the industry’s forefront.

swop 2025 concentrated on core packaging themes — artificial intelligence and digital packaging; sustainable materials and circular design; and lightweight and customized solutions. The exhibition delivered a systematic, one-stop industry-chain showcase spanning processing and packaging machinery, material innovation, packaging products, label printing, and packaging design. The 2025 edition set a new scale record: exhibition space exceeded 70,000 square meters, and the show brought together over 950 exhibitors from around the world, featuring international pavilions from Germany, Italy, Austria, France, Turkey, Switzerland, Japan, and South Korea. Over the three-day period, the exhibition was expected to draw more than 40,000 trade visitors and buyers from China and abroad to Shanghai.

Launching a new global chapter: from 2026, swop will be renamed as ‘interpack China‘

On the morning of November 25, the swop 2025 opening ceremony — themed “A Decade of Brilliance — A New Chapter” — took place at SNIEC. Ms. Evian Gu, General Manager of Messe Düsseldorf (Shanghai) Co., Ltd.; Ms. Rita Chu, Vice Chairman of The Adsale Group; and Mr. Thomas Dohse, Director interpack, Portfolio Processing & Packaging of Messe Düsseldorf GmbH, attended the ceremony and delivered speeches. Representatives from key partners and industry bodies — including the Shanghai Packaging Technology Association; the CCPIT Machinery Sub-Council; the Zhejiang Health Products & Cosmetics Industry Association; the Shanghai Society of Plastic Industry; the Shandong Plastics Association; and the Nanjing Food Industry Association— participated in the launch. More than 30 representatives from prominent industry firms and professional media outlets were also present to witness the event.

At this ten-year milestone, the Shanghai World of Packaging (swop) will undergo a major upgrade: beginning in 2026, the exhibition will be officially renamed as ‘interpack China‘. This change is more than a renaming: it signals the show’s intent to deepen integration with the global packaging ecosystem and to broaden its international outlook. As a member of the interpack global alliance and drawing on its international resources, interpack China will continue to bring together leading global technologies, ideas and expertise to enrich the experience for exhibitors and visitors and to serve as a central platform for advancing packaging innovation. Going forward, interpack China will collaborate with partners worldwide to explore opportunities in intelligent manufacturing, innovative materials, and talent development — injecting fresh momentum into the global packaging industry ecosystem.

swop 2025 introduces eight themed routes to address 24 packaging “pain points”

This year, swop once again launched its “Signature Packaging Routes,” enhancing on-site sourcing for trade buyers and visitors. The concurrent program targeted widespread industry needs, presenting eight themed routes that address 24 specific packaging “pain points,” and offering end-to-end solutions across the value chain — from equipment and materials to design and logistics. Exhibits spanned key areas including plastic and paper container production (equipment and materials), primary and secondary packaging machinery, packaged products, and logistics packaging. The routes directly addressed trade buyers’ and visitors’ core requirements — product traceability, production efficiency, accuracy, and finished-product yield — and on the first day of the show they drew unanimous praise and strong interest from exhibitors and trade buyers.

A series of concurrent forums and events were held, showcasing global packaging innovations and international market insights.

– 2025 SAVE FOOD Forum and Awarding Ceremony for Save Food Design Award & Sustainability Design Award China

For the fifth time, swop partnered with the Food and Agriculture Organization of the United Nations Representation in China (FAO China) to host the SAVE FOOD Forum. This year’s forum brought together policy makers, designers and technologists to discuss strategies for reducing food loss and waste. The program featured three roundtable discussions: The Intersection of Sustainable Food Systems and Packaging: Women Power in the Industry; Innovation and Technology in Sustainable Packaging; and Global Design for Recycling Guidelines: Tools for Creating Recyclable Packaging. Concurrently, the Awarding Ceremony for Save Food Design Award & Sustainability Design Award China — organized by Messe Düsseldorf together with the World Packaging Organisation (WPO), FAO China and the United Nations Industrial Development Organization (UNIDO) — was held during the event.

– Global Emerging Technologies: An international look at emerging packaging technologies and trends to help attendees identify future directions.

Leveraging its membership in the interpack alliance, swop tapped the alliance’s global network and professional resources to deliver one-stop processing and packaging solutions for buyers across food, beverage, pharmaceuticals, cosmetics, confectionery, bakery, non-food consumer goods, and industrial sectors. swop 2025 places attendees at the epicenter of global packaging compliance, with leading companies and innovation pioneers from Germany, Italy, Austria, France, Turkey, Switzerland, Japan and South Korea showcasing on-site cutting-edge technologies in digitalization, intelligent automation and low-carbon, sustainable packaging.

Furthermore, swop 2025 presented a full programme of specialist forums addressing market strategy, digitalization, green packaging, food-processing technologies and business matchmaking. Key sessions included: Packaging Industry • Practical Forum on Starting from Zero in Cross-Border Trade; Navigation New Markets in Packaging’s Blue Ocean; swop x CPRJ The Digital and Intelligent Carbon Reduction Revolution in Plastic Packaging — From Material Innovation to Circular Ecosystem; Industry-University-Research Cooperation Conference on Packaging Industry 2025 & The 2nd Training Course for Sustainable Packaging Engineers; interpack 2026 Press Conference; and Dialogue Across Continents: Eurasian Food Packaging Technology and Business Opportunity Connection Forum. These events featured presentations and panel discussions by international experts who shared insights on packaging market demand, helping Chinese packaging companies expand overseas and fostering collaboration between domestic and international industry players under the theme of global resource connectivity and co-creation of value. We look forward to your participation.

Smart supply chains, global intelligence: swop 2025 showcases intelligent primary and secondary packaging equipment and technologies

swop 2025 introduced for the first time the “Scenario Smart Connect — Packaging Solutions Zone” in Hall N4. This dedicated zone addressed the needs of trade buyers by providing in-depth industry trend analysis, guidance on overseas-market compliance, forward-looking technology showcases, and expert sessions that dissect common production pain points. The exhibition also featured two interactive areas — the Packaging Decision Accelerator and the Packaging Challenge Arena — where equipment connectivity and coordinated intelligent solutions were demonstrated in live, application-driven settings. In addition to technology showcases, the Zone functioned as a commercial exchange platform for industry specialists and buyers to explore cooperation and partnership opportunities. Visitors could experience the demonstrations at Booth K05 in Hall N4.

Wide industry support: swop 2025 backed by domestic and international associations

swop 2025 received strong support from a broad network of domestic and international industry organizations, as well as from leading trade media. Key institutional partners included the Shanghai Packaging Technology Association (PTA), the Food and Agriculture Organization of the United Nations (FAO), the United Nations Industrial Development Organization (UNIDO), the World Packaging Organisation (WPO), , the VDMA Food Processing and Packaging Machinery Association, the Korea Packaging Association (KOPA), and the CCPIT Machinery Sub-Council. Furthermore, the event was supported by more than 100 domestic and international industry associations representing the food, cosmetics, plastics and printing & packaging sectors.

Join us in Shanghai for the three-day swop 2025 and discover the pulse of the packaging world! trends.

About swop

Messe Düsseldorf (Shanghai) Co., Ltd. and Adsale Exhibition Services Ltd. will join hands once again to present the Shanghai World of Packaging (swop) at Shanghai New International Expo Centre from 25 to 27 November 2025. Shanghai World of Packaging (swop), as a member of the interpack alliance, the world’s leading packaging machinery and processing exhibition, will make full use of the interpack alliance’s global network and professional resources to provide an excellent trade display platform for domestic and foreign processing and packaging machinery manufacturers, packaging material production suppliers. swop will provide one-stop processing and packaging solutions for end buyers of Food, Beverage, Sweets, Bakery, Pharmaceutical, Cosmetics, Non-food and Industrial Goods Packaging.

For more information, please visit the official website: www.swop-online.com or follow the official QR code below to stay tuned with the latest Shanghai World of Packaging (swop) news.

About the Organizers

Messe Düsseldorf (Shanghai) Co., Ltd.

Established in 2009, Messe Düsseldorf (Shanghai) Co., Ltd. (MDS) is a subsidiary of Messe Düsseldorf GmbH, one of the world’s top 5 exhibition organizers. MDS is committed to introducing world’s No. 1 trade fairs to China and to providing Chinese and international customers with superior exhibition services. MDS is successfully holding more than 20 leading trade fairs and conferences in China, covering the industries of printing, packaging, wire and tube, plastics, renewable energy, medical devices, retail, safety and health, wine & spirits and caravanning. MDS runs branch offices in Shanghai and Beijing with a workforce of some 70 full time employees. The worldwide outbound exhibition business (trade shows in Düsseldorf, Germany and other leading Messe Düsseldorf Global Shows) is organized by Messe Düsseldorf China Ltd. (MDC), serving Chinese exhibitors and visitors with superior customer service from its Hong Kong branch office. Find out more at www.mds.cn

Adsale Exhibition Services Ltd.

Adsale Exhibition Services Ltd has been established in Hong Kong since 1978. It is the organizer of Chinaplas, the Asia’s no. 1 exhibition in the plastics and rubber industries. Adsale is also the organizer of Sino-Pack, PACKINNO, Sino-Label and Printing South China, etc. Backed up with enormous resources in Asia and with well-versed trade promotion strategies for the Chinese market, Adsale is endeavoring to provide cost-effective and integrated marketing solutions across various industries, to satisfy international suppliers’ needs of tapping into the Chinese and Asian markets. The Group has offices in Beijing, Shanghai, Shenzhen and Singapore. Website: www.adsale.com.hk

SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). This application of mazdutide 9 mg aims to address a pressing unmet clinical need in China by offering a highly effective and safe new treatment option for adults with moderate-to-severe obesity, beyond current standard-of care metabolic and bariatrics surgery.

This application is based on the encouraging results from the Phase 3 registration clinical study GLORY-2 (NCT06164873) of mazdutide 9 mg in Chinese adults with moderate to severe obesity. The study met its primary endpoints and all key secondary endpoints. [Link]

• At Week 60, participants in the mazdutide group exhibited continuous weight loss, with no plateau observed. The mazdutide 9 mg group achieved a mean weight reduction of 18.55%, compared to 3.02% in the placebo group. 44.0% of participants in the mazdutide 9 mg group achieved a weight reduction of 20% or more, versus 2.6% in the placebo group (P<0.0001 for all comparisons).
• The key secondary endpoints also demonstrated that mazdutide 9 mg achieved a weight loss of up to 20.08% at Week 60 among participants without type 2 diabetes, with the weight loss trend not yet reaching a plateau by the end of the study. Furthermore, nearly half (48.7%) of the non-diabetic participants achieved weight loss exceeding 20% (placebo: 3.1%; P<0.0001).
• Additionally, the study observed that mazdutide 9 mg significantly reduced liver fat content, with a mean percent reduction from baseline of 71.9%, and also demonstrated significant improvements in other key cardiometabolic endpoints, including blood pressure, blood lipids, and serum uric acid, as well as significant reduction in waist circumference.
• Mazdutide 9 mg exhibited a favorable safety profile, with no new safety signals identified.
• Detailed data from the GLORY-2 study, which met all its endpoints, are planned for disclosure at future international academic conferences or in scientific publications.

Professor Linong Ji, the leading principal investigator of the study, Peking University People’s Hospital, stated, “In China, individuals with severe obesity (BMI > 32.5 kg/m²) face a substantial disease burden but have very limited treatment options. According to current Chinese clinical guidelines, metabolic surgery is recommended as a first-line treatment for such patients. However, the invasiveness of the procedure and patient apprehension significantly limit its widespread clinical application. The potent weight loss efficacy demonstrated by mazdutide 9 mg in the GLORY-2 study positions it as a highly promising alternative to metabolic surgery, potentially filling a major clinical gap. Its benefits across multiple metabolic parameters highlight the unique advantages of dual GCG/GLP-1 activation. The acceptance of this application marks the potential addition of another breakthrough therapy for the management of moderate to severe obesity in China, bringing new hope for improving the health of this population.”

Dr. Lei Qian, Chief R&D Officer of General Biomedicine of Innovent, stated, “Mazdutide 9 mg is currently the only GLP-1 receptor agonist that achieves over 20% weight loss in obese adults without T2D after 1 year of treatment with just a 2-step dose titration. Its development provides evidence-based medical support for effective weight management in Chinese patients with moderate-to-severe obesity, offering an alternative to metabolic surgery. We are delighted that the supplementary application for mazdutide has been accepted. Our strategic portfolio—ranging from 2mg-4mg-6mg targeting the broad overweight/obese population, to the 3 mg-6mg-9mg dosage now targeting the severely obese population—is built upon profound scientific insight and clear market needs. It is designed to provide a ‘stratified,’ personalized solution precisely tailored to the treatment goals and clinical needs of obese patients at different levels of disease severity. Innovent will continue to strategically build our next-generation product pipeline in the cardiovascular and metabolic (CVM) field, and help people’s pursuit of a healthy life.”

About Mazdutide

Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG/GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improved insulin sensitivity.

Innovent has currently conducted or completed seven Phase 3 clinical studies of mazdutide, including:

• GLORY-1: A Phase 3 clinical study conducted in Chinese adults with overweight of obesity;
• GLORY-2: A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity;
• DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes;
• DREAMS-2: A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with type 2 diabetes who have poor glycemia control with oral medication;
• DREAMS-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity;
• GLORY-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);
• GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity.

Among these, the first five Phase 3 clinical studies have all met their primary endpoints, while the remaining two Phase 3 studies are still ongoing.

In addition, several clinical studies of mazdutide are ongoing in adolescents with obesity, patients with metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF) etc.

Mazdutide has earned widespread recognition supported by robust data set. Its Phase 2 clinical trial in Chinese subjects with overweight or obesity was selected by Nature Communications as one of the 50 most important studies in translational and clinical research and highlighted as Editor’s Choice. Additionally, mazdutide was listed among the “Top 10 Most Anticipated Drug Launches of 2025” by the FIERCE Pharma.

Furthermore, clinical findings on mazdutide have been featured in top-tier international journals such as The New England Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, as well as presented at leading scientific conferences including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) annual meetings. Notably, mazdutide is the first innovative drug in China’s endocrinology and metabolism field to have clinical results published in The New England Journal of Medicine, underscoring its significant clinical value.

Mazdutide has received NMPA approval for two indications:

First Indication: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:

• BMI ≥ 28 kg/m² (obesity); or
• BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome).

Second Indication: For glycemic control in adults with type 2 diabetes.

Monotherapy:

For adults with type 2 diabetes who have inadequate glycemic control despite diet and exercise interventions.

Combination Therapy:

For adults with T2D who still have poor glycemic control despite:

• Diet and exercise, plus metformin and/or sulfonylureas;
• Diet and exercise, plus metformin and/or SGLT2 inhibitors (SGLT2i).

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.